All sponsors

BeBetter Med Inc

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS7
PHASE 3 / 2-33
RECRUITING6
READOUTS ≤12 MONTHS1
Open BeBetter Med Inc on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
BEBT-109 Capsule
NCT06706713
P2RecruitingNon-Small Cell Lung Cancer; EGFR Exon 20 Insertion Mutation2002025-12-31
BEBT-209 capsules
NCT06998108
P3RecruitingHR+/HER2- Locally Advanced, Metastatic Breast Cancer3302025-12-31
BEBT-109 Capsules
NCT06514027
P2RecruitingNon Small Cell Lung Cancer302027-06
Ifupinostat Hydrochloride for Injection
NCT07676175
P2Not yet recruitingPreviously Untreated Peripheral T-Cell Lymphoma1202028-01-31
BEBT-701 Injection
NCT07368608
P1/2RecruitingMild to Moderate Hypertension and Elevated Low-Density Lipoprotein Cholesterol3402028-11-30
Ifupinostat Hydrochloride for Injection
NCT06792253
P3RecruitingRelapsed/Refractory Diffuse Large B-Cell Lymphoma4162028-12-31
BEBT-209 capsules
NCT07544056
P2/3RecruitingLocally Advanced Triple-negative Breast Cancer; Metastatic Triple-negative Breast Cancer4462030-06